Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES

Inclusion Criteria: * Patient is at least 18 years old * Patients is a suitable candidate for Percutaneous Coronary Intervention (PCI) * Patient has multi-vessel disease with ≥2 de-novo lesions in native coronary arteries suitable for treatment with TCD-10023 DES * Target lesions are suitable for OFDI examination; * Patient requires staged procedure between 3-5 weeks after baseline procedure, according to investigator's judgement * Target vessel reference diameter is between 2.5 - 4.0 mm (visual assessment) * Patient has provided written informed consent * Patient is affiliated to social security or equivalent system (France only) Exclusion Criteria: * \- Patient has known allergy to sirolimus, cobalt, chromium, nickel, or contrast agent (that cannot be adequately premedicated) * Patient is not a suitable candidate for use of Dual Anti-Platelet Therapy (DAPT) because of active or recent bleedings or for use of vitamin K antagonist, like warfarin, dabigatran, rivaroxaban or acenocoumarol; * Patient is presenting with ST-segment elevated MI (STEMI) at baseline procedure * Patient has Killip-class \> 1 at admission * Patient is in cardiogenic shock * Patient is a female of childbearing potential * Patient has life expectancy of less then 1 year * Patient is expected to undergo major surgery within 3 months * Patient has Left Main disease ≥ 50% * Target lesion at bifurcation requiring 2 stents technique * Target lesions are severely calcified * Target lesion is located within 3 mm of aorta-ostium * Patient has renal failure defined as estimated Glomerular Filtration Rate (eGFR) \<50 mL/min/1.73m² * Target lesions require preparation other than balloon pre-dilatation * Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials * In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study * Patient is under judicial protection (France only)